My Favorites
My Favorites
Add Page
Add Page
Print
Print
You have 0 items saved in "My Favorites"
Use "My Favorites" to collect pages, downloads, properties, companies, and reports that you would like to keep in one place. To store a page, click on the "Add to My Favorites" button at the top of the page. To store a download, click on the plus button next to the download link. To store a property or company or community, click on the "Add to My Favorites" button listed next to each listing. Reports that are generated are automatically saved to My Favorites. My Favorites will be saved for seven days.

AveXis


Rare diseases don’t feel rare to the families devastated by them. They create daily challenges that must be faced head-on, often without the help of readily available treatment.
 
With cutting-edge technology, we are making progress in the treatment of rare and life-threatening neurological genetic diseases. Our initial proprietary investigational gene replacement therapy, AVXS-101 (onasemnogene abeparvovec-xioi) is in development for the treatment of spinal muscular atrophy (SMA), and we are also pursuing gene therapies for Rett syndrome (AVXS-201) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301).
 
We are headquartered in Bannockburn, IL, with manufacturing facilities in the Chicago, IL, Durham, NC and Longmont, CO areas. Our Research and Development site is located in La Jolla, CA. European headquarters are located in Zurich, Switzerland and AveXis KK is located in Tokyo, Japan.
 
Longmont Economic Development Partnership
1925 Pike Road, Suite 202
Longmont, CO 80501
Site Map
¬© 2015 Longmont Economic Development Partnership © Powered by Community Systems Site created by Atlas Advertising